MYGN - Myriad Genetics, Inc.
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa as chief technology officer (CTO), effective June 1, 2026. “Raj is a proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise,” said Sam Raha, Chief Executive Officer, Myriad Genetics.
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
SALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces it will share data demonstrating the utility of Myriad's Precise MRD™ (molecular residual disease) test across diverse cancer types. Myriad will share evidence across six poster presentations showcasing the prognostic power of its ultrasensitive MRD assay.
SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.1-4 This combination helps identify if a patient is safe for active surveillance (AS) and how refinement of AS intensity can be personalized.4-8 This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company.
Myriad (MYGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jackie Tohn to raise awareness about the importance of hereditary cancer testing with the MyRisk ® Hereditary Cancer Test. Through conversations with her physician and genetic testing, Tohn discovered she carried a BRCA1 gene variant after her father was diagnosed with cancer and tested positive for the same variant.
SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jackie Tohn to raise awareness about the importance of hereditary cancer testing with the MyRisk Hereditary Cancer Test.
SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The BofA Securities 2026 Health Care Conference – 1-to-1 investor meetings taking place Wednesday, May 13, 2026.
Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript
Myriad Genetics (MYGN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.03 per share a year ago.
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.
The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind.